Review summary
Teaching objective: Evaluate an adult after a generalized seizure as the AAN/AES first unprovoked seizure guideline directs: history, examination and laboratory screen, EEG, and MRI of the brain with susceptibility-weighted imaging, which here shows a cavernous malformation; diagnose epilepsy after a single unprovoked seizure when an epileptogenic lesion makes recurrence likely (ILAE 2014 practical definition); choose an antiseizure medication for a woman who could become pregnant (levetiracetam or lamotrigine, with folic acid, contraception counseling and the reasons to avoid valproate, under the AAN/AES/SMFM 2024 guideline); refer for neurosurgical evaluation of an epileptogenic cavernous malformation and consider lesionectomy (Angioma Alliance 2017); tell her about SUDEP and how to lower the risk, as the AAN/AES 2017 guideline requires; give seizure safety advice for driving under California law, water and sleep, with nocturnal seizure detection; and plan a safe return to elite-level training.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| December 21, 1959 | Born in Los Angeles; grows up in Watts. | CLM-0001 |
| 1983 | Graduates from UCLA. | CLM-0002 |
| 1984 | Olympic silver medal in the 200 meters, Los Angeles. | CLM-0002 |
| 1988 | World records at 100 and 200 meters; three Olympic gold medals and a silver in Seoul. | CLM-0003 |
| 1989 | Retires from competition. | CLM-0003 |
| 1990 to 1994 | Treated for seizures in 1990, 1993 and 1994, as later reported from the coroner's records. | CLM-0006 |
| 1993 | Co-chair of the President's Council on Physical Fitness and Sports. | CLM-0004 |
| 1995 | Inducted into the U.S. Track and Field Hall of Fame. | CLM-0004 |
| April 1996 | Seizure on a flight to St. Louis; discharged from hospital the next day. | CLM-0005 |
| September 21, 1998 | Dies in her sleep at home in Mission Viejo, California, at 38; the coroner reports positional asphyxia during an epileptic seizure caused by a cavernous angioma. | CLM-0007 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Florence Griffith was born in Los Angeles on December 21, 1959, the seventh of eleven children, and grew up from the age of four in a public housing project in the Watts neighborhood of Los Angeles. Reference works give her given names in both orders, Delorez Florence and Florence Delorez. | confirmed | Florence Griffith Joyner (athlete profile) supports Griffith Joyner, Florence (biographical entries) supports HISTMED Master Roster v3 context |
| D | She ran for California State University, Northridge, and then for UCLA, graduating in 1983, and won the silver medal in the 200 meters at the 1984 Olympic Games in Los Angeles, competing as Florence Griffith. Anchors the modern social history of an elite sprinter. |
confirmed | Griffith Joyner, Florence (biographical entries) supports Florence Griffith Joyner (athlete profile) supports |
| D | In 1988 she set a world record of 10.49 seconds for 100 meters at the U.S. Olympic Trials and, at the Seoul Olympic Games, won gold medals in the 100 meters, the 200 meters (in a world record of 21.34 seconds) and the 4 x 100 meters relay, and a silver medal in the 4 x 400 meters relay. She retired from competition in 1989. Her athletic career anchors the modern goal of returning to training. |
confirmed | Florence Griffith Joyner (athlete profile) supports Griffith Joyner, Florence (biographical entries) supports No direct drug link to FloJo death supports |
| D | In 1993 she was appointed co-chair of the President's Council on Physical Fitness and Sports, and in 1995 she was inducted into the U.S. Track and Field Hall of Fame. She also worked as a designer of clothing and athletic wear. Her work in fitness and design anchors the modern social history. |
confirmed | Griffith Joyner, Florence (biographical entries) supports Joyner autopsy reveals seizure (The Associated Press) context |
| D | In April 1996 she had a seizure on an airplane on the way to St. Louis. She was taken to hospital and discharged the next day, and her family asked that no other details be released. Reported during her life: the first publicly known seizure and the anchor for the modern episode, which begins about two and a half weeks later. |
confirmed | Flo Jo reportedly doing fine after having seizure on plane (The Associated Press) supports Griffith Joyner, Florence (biographical entries) supports |
| D | Coroner's investigation records, reported after her death, state that she had a generalized (grand mal) seizure in 1990 and had been treated for seizures in 1990, 1993 and 1994. Earlier seizure history known only from records published after her death; it is recorded as history and is not expanded in the modern episode. |
probable | Rebelo Anderson K. The uneasy death of Florence Griffith Joyner supports |
| D | She died in her sleep at her home in Mission Viejo, California, on September 21, 1998, at 38. The Orange County Sheriff-Coroner reported that she died of positional asphyxia during an epileptic seizure, and that the seizure was caused by a congenital cavernous angioma (cavernous malformation) of the left orbital frontal cerebrum. The documented disease to which the synthetic diagnosis is linked. History only, stated without detail. |
confirmed | No direct drug link to FloJo death supports Joyner autopsy reveals seizure (The Associated Press) supports Autopsy proves Flo-Jo suffered an epileptic seizure supports Rebelo Anderson K. The uneasy death of Florence Griffith Joyner supports Florence Griffith Joyner (athlete profile) supports Seizure, suffocation caused Flojo's death supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Generalized tonic-clonic seizure on a flight two and a half weeks ago, in a 36-year-old woman who was observed overnight in hospital elsewhere and has had treatment for seizures in the past, records requested; no antiseizure medication now; normal examination today. Evaluated as a new seizure: EEG and MRI of the brain with susceptibility-weighted imaging ordered, neurology (epilepsy) review booked, and no driving | resolved | confirmed | active | CLM-0005, CLM-0006 |
| S | Focal epilepsy with structural cause: focal to bilateral tonic-clonic seizure from a left orbitofrontal cavernous malformation, with left frontal epileptiform discharges on EEG; epilepsy under the ILAE 2014 practical definition (an unprovoked seizure with a recurrence risk above 60% from an epileptogenic lesion, and earlier seizures by history); synthetic modern detail linked to her publicly reported seizures and the coroner's finding | active | confirmed | both_with_link | CLM-0005, CLM-0006, CLM-0007 |
| S | Solitary cerebral cavernous malformation, 1.4 cm, left orbitofrontal cortex, with a hemosiderin rim and an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging (sporadic pattern); no acute hemorrhage | resolved | confirmed | active | CLM-0007 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-04-22 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-22 | Leukocytes [#/volume] in Blood by Automated count | 6.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-04-22 | Platelets [#/volume] in Blood by Automated count | 238 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-04-22 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-22 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-22 | Glucose [Mass/volume] in Serum or Plasma | 86 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-22 | Calcium [Mass/volume] in Serum or Plasma | 9.6 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-04-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-22 | Magnesium [Mass/volume] in Serum or Plasma | 2 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2026-04-22 | Creatine kinase [Enzymatic activity/volume] in Serum or Plasma | 168 U/L Reference 26-192 U/L |
http://loinc.org · 2157-6 |
| S | 2026-04-22 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-04-22 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-05-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-08-25 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-04-22 | Body height | 170 cm | 8302-2 | S |
| 2026-04-22 | Body weight | 61 kg | 29463-7 | S |
| 2026-04-22 | Body mass index (BMI) [Ratio] | 21.1 kg/m2 | 39156-5 | S |
| 2026-04-22 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-04-22 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-04-22 | Heart rate | 56 /min | 8867-4 | S |
| 2026-04-22 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-22 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-04-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-05-05 | Body height | 170 cm | 8302-2 | S |
| 2026-05-05 | Body weight | 61.2 kg | 29463-7 | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 21.2 kg/m2 | 39156-5 | S |
| 2026-05-05 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-05-05 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-05-05 | Heart rate | 58 /min | 8867-4 | S |
| 2026-05-05 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-05 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-05-27 | Body height | 170 cm | 8302-2 | S |
| 2026-05-27 | Body weight | 60.8 kg | 29463-7 | S |
| 2026-05-27 | Body mass index (BMI) [Ratio] | 21 kg/m2 | 39156-5 | S |
| 2026-05-27 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 2026-05-27 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-05-27 | Heart rate | 60 /min | 8867-4 | S |
| 2026-05-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-27 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-05-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-07-21 | Body height | 170 cm | 8302-2 | S |
| 2026-07-21 | Body weight | 60.1 kg | 29463-7 | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 20.8 kg/m2 | 39156-5 | S |
| 2026-07-21 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-07-21 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-07-21 | Heart rate | 62 /min | 8867-4 | S |
| 2026-07-21 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-10-20 | Body height | 170 cm | 8302-2 | S |
| 2026-10-20 | Body weight | 60.9 kg | 29463-7 | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 21.1 kg/m2 | 39156-5 | S |
| 2026-10-20 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-10-20 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-10-20 | Heart rate | 54 /min | 8867-4 | S |
| 2026-10-20 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-20 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-25 | Body height | 170 cm | 8302-2 | S |
| 2026-08-25 | Body weight | 60.6 kg | 29463-7 | S |
| 2026-08-25 | Body mass index (BMI) [Ratio] | 21 kg/m2 | 39156-5 | S |
| 2026-08-25 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 2026-08-25 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 2026-08-25 | Heart rate | 56 /min | 8867-4 | S |
| 2026-08-25 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-25 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Former Olympic sprinter and world-record holder; designs clothing and athletic wear and works in youth fitness; still trains most days, with sprint, track and weight sessions
- S Married, with a young child; household members are not named and have no role in this record. Supports: her household, her training community, and the young athletes she works with
- S Values her privacy about her health and decides who is told
- S Never smoker; alcohol rarely; no drug use; caffeine one coffee a day
- S Drives herself to training and work; swims for recovery; flies often for work
Functional status
- S Independent; training at a high level; no lasting weakness or memory problem after the seizure
Mental status
- S Alert, poised and engaged; no memory of the seizure itself; worried about another seizure in public; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily
- S Folic acid 0.4 mg oral tablet, one tablet daily
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day
Procedures and immunizations
Procedures
- S Routine EEG with sleep deprivation the night before, awake and asleep, with hyperventilation and photic stimulation: intermittent left frontal sharp waves and focal slowing (maximum F7 and Fp1); no generalized discharges; no seizure recorded
- S MRI of the brain, epilepsy protocol, with susceptibility-weighted imaging and gadolinium: a 1.4 cm mulberry-like lesion in the left orbitofrontal cortex with mixed signal and a complete hemosiderin rim (cavernous malformation, Zabramski type II), an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging, and no acute hemorrhage or edema
- S Advance care planning conversation, about 15 minutes
- S Left frontal craniotomy with neuronavigation for complete excision of the orbitofrontal cavernous malformation with the surrounding hemosiderin-stained brain, sparing the developmental venous anomaly; no complications; home on the third day. Pathology: cavernous malformation (closely packed, thin-walled vascular channels without intervening brain, with old hemorrhage and hemosiderin in the surrounding gliotic tissue)
- S MRI of the brain the day after surgery: complete resection of the cavernous malformation and the hemosiderin rim; expected postoperative changes; developmental venous anomaly preserved; no hemorrhage or infarct
Immunizations
- S 2026-08-25: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1990 to 1994: Treated for seizures in 1990, 1993 and 1994, as reported from the coroner's records after her death; details not public (CLM-0006)
- D April 1996: Seizure on a flight in April 1996; discharged from hospital the next day; the family asked that no other details be released (CLM-0005)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks | 2026-05-05 | completed | EEG in two days, MRI in six, consultation at two weeks |
| No further seizures on an antiseizure medication she tolerates | 2026-10-20 | completed | No seizure in six months; levetiracetam tolerated after early irritability settled |
| Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months | 2026-07-21 | completed | Seen by neurosurgery at three weeks; complete lesionectomy at eight weeks |
| Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan | 2026-05-27 | completed | Driving stopped and reported as California requires; SUDEP discussed (one visit late, recorded as a deviation); detection watch in use |
| Graded return to full sprint training within four months of surgery | 2026-10-20 | completed | Full training at four months after surgery |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Neurology (epilepsy) consultation within two weeks to interpret the EEG and MRI, decide whether this is epilepsy, and advise on antiseizure medication, surgery and safety | completed | GL-AAN-FIRSTSZ-2015, GL-ILAE-DEF-2014 |
| Evaluation of a seizure in an adult: history from her and witnesses' accounts, examination, blood count, electrolytes, glucose, calcium, magnesium, kidney and liver tests and creatine kinase, a pregnancy test, a sleep-deprived EEG, and MRI of the brain with an epilepsy protocol including susceptibility-weighted imaging; records of her earlier seizure care requested | completed | GL-AAN-FIRSTSZ-2015 |
| Safety from today: no driving, and the report of a disorder characterized by lapses of consciousness that California requires of physicians, explained to her before it is sent; no swimming alone or bathing in a tub, showers instead; no heights or working alone near water; seizure first aid and a written seizure action plan, calling emergency services for a seizure lasting five minutes or more | completed | GL-CA-DMV-2024, GL-AAN-FIRSTSZ-2015 |
| Levetiracetam 500 mg twice daily, chosen for a woman who could become pregnant (low risk of birth defects, no interaction with hormonal contraception), with folic acid 0.4 mg daily; valproate avoided because of its risk of major malformations and lower intelligence in children exposed in pregnancy; contraception and pregnancy planning discussed; mood and irritability checked with the PHQ-9 at each visit | completed | GL-AAN-TERATO-2024, GL-AAN-FIRSTSZ-2015, GL-ILAE-DEF-2014 |
| Neurosurgical evaluation of the epileptogenic cavernous malformation, with lesionectomy including the hemosiderin rim if she chooses it | completed | GL-CCM-2017 |
| SUDEP counseling as the AAN/AES guideline requires: what it is, that tonic-clonic seizures are the main risk, and how to lower it (take every dose, keep regular sleep, avoid alcohol excess, aim for no tonic-clonic seizures); nocturnal supervision or a seizure detection watch | completed | GL-AAN-SUDEP-2017, GL-ILAE-DETECT-2021 |
| Graded return to training after surgery: walking and stationary cycling from two weeks, running from four to six weeks, sprint sessions from six to eight weeks, full training by three to four months, with no heavy lifting until the craniotomy has healed; swimming only with a companion who knows seizure first aid | completed | GL-CCM-2017, GL-AAN-FIRSTSZ-2015 |
| Long term: levetiracetam for at least two years after surgery, then a shared decision about tapering with an EEG; driving when the California DMV clears her after a seizure-free period; MRI only for new symptoms after a complete resection | completed | GL-CCM-2017, GL-CA-DMV-2024, GL-AAN-FIRSTSZ-2015 |
Planned encounters
- 2026-04-22 — Two and a half weeks after a generalized seizure on a flight: history, examination, laboratory screen, EEG and MRI ordered, driving and safety advice, and neurology (epilepsy) review booked (ENC-001)
- 2026-05-05 — EEG and MRI results: focal epilepsy from a left orbitofrontal cavernous malformation; epilepsy consultation, levetiracetam with folic acid, and neurosurgical opinion requested (ENC-002)
- 2026-05-27 — Three weeks on levetiracetam: mood and side effects, the neurosurgical opinion and surgery date, SUDEP and safety counseling (ENC-003)
- 2026-07-21 — Five weeks after lesionectomy: recovery, seizure control, return to training (ENC-004)
- 2026-08-25 — Periodic adult preventive visit (ENC-006)
- 2026-10-20 — Six months after the seizure: seizure freedom, driving review, training, and the long-term plan (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Neurology (epilepsy) referral
- Neurology (epilepsy) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Neurology (epilepsy) referral (XML)
- Neurology (epilepsy) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Florence Griffith Joyner (athlete profile) | Olympedia | biography |
| SRC-0002 | Griffith Joyner, Florence (biographical entries) | Encyclopedia.com | biography |
| SRC-0003 | Flo Jo reportedly doing fine after having seizure on plane (The Associated Press) | The Spokesman-Review | other |
| SRC-0004 | Rebelo Anderson K. The uneasy death of Florence Griffith Joyner | Salon | other |
| SRC-0005 | No direct drug link to FloJo death | The Irish Times | other |
| SRC-0006 | Joyner autopsy reveals seizure (The Associated Press) | CBS News | other |
| SRC-0007 | Autopsy proves Flo-Jo suffered an epileptic seizure | World Athletics (IAAF) | other |
| SRC-0008 | Seizure, suffocation caused Flojo's death | Deseret News | other |
| SRC-0009 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the ILAE 2014 diagnosis after one seizure with a cavernous malformation (and earlier seizures by history), levetiracetam rather than lamotrigine, early lesionectomy after one evaluated seizure, the California reporting duty, the SUDEP counseling and its one-visit delay, and the return-to-training schedule. |
| provenance review | not_started | Recent-death rule: only what was reported during her life (the Associated Press report of the 1996 seizure) and the coroner's findings as reported by news organizations and World Athletics, plus Olympedia and Encyclopedia.com for her life and career. The earlier treated seizures come from coroner's records reported by Salon and are graded probable. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named or given a role in the modern episode, and no statement, decision or health fact is attributed to any relative. Rumors about performance-enhancing drugs are not part of the clinical record. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.